Teva denies big layoffs are planned, but will push greater efficiency and shutter floundering efforts
With its executive suite in turmoil, its flagship drug under attack and its books burdened by debt following years of drought in its R&D arm …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
